Regeneron price target lowered to $1,126 from $1,137 at Truist
The Fly

Regeneron price target lowered to $1,126 from $1,137 at Truist

Truist lowered the firm’s price target on Regeneron (REGN) to $1,126 from $1,137 and keeps a Buy rating on the shares after its Q3 results. Investor focus has been on Eylea and Eylea HD conversion, but the firm maintains that Regeneron’s broad pipeline across oncology, internal/genetic medicines, I&I and ophthalmology remains overlooked, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App